Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation.
about
Virtual screening as a strategy for the identification of xenobiotics disrupting corticosteroid actionA combination of receptor-based pharmacophore modeling & QM techniques for identification of human chymase inhibitorsAccessing biological actions of Ganoderma secondary metabolites by in silico profilingIdentification of novel liver X receptor activators by structure-based modelingAn updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters.Discovery of novel, non-acidic mPGES-1 inhibitors by virtual screening with a multistep protocol.Hit Identification of a Novel Dual Binder for h-telo/c-myc G-Quadruplex by a Combination of Pharmacophore Structure-Based Virtual Screening and Docking Refinement.Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators.Characterizing ligands for farnesoid X receptor--available in vitro test systems for farnesoid X receptor modulator development.Identification of potential dual agonists of FXR and TGR5 using e-pharmacophore based virtual screening.Simultaneous diastereo- and enantioseparation of farnesoid X receptor (FXR) agonists with a quinine carbamate-based chiral stationary phase.Identification of InhA inhibitors: A combination of virtual screening, molecular dynamics simulations and quantum chemical studies.Discovery of new FXR agonists based on 6-ECDCA binding properties by virtual screening and molecular docking
P2860
Q28484229-878F568B-25BC-4866-895B-1FECD51096E0Q28487136-73263F13-6726-44A6-A9B7-0D005F0A3C59Q28829917-3B79EA8C-9EED-4766-9284-0DC1B53FEABFQ34226831-B76253C4-7CD6-4F2C-99A0-BFFA290FB178Q35206374-14A32125-B644-41F0-9D8C-F50D7AB892DDQ35667896-3B0F0330-8BD5-46AA-959A-0A904260699CQ35967905-307EF23F-A724-4524-BC0A-A3D4AF8B3504Q38014901-C4B683FA-DCA8-4DFD-A609-9FB5FDFDA778Q38164798-9B7201F5-977B-4571-A485-6723EA69DB73Q38897837-47A84AB8-7218-4103-821F-3C46FF66638DQ46739028-C838E596-2F01-4B5F-B1BD-AABDBC8CF1E9Q53092961-83B7EC0D-9590-4ECD-9E8A-2B04729CC4A1Q58568698-959434AC-C8CB-47B0-B60E-735244E31E69
P2860
Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Pharmacophore-based discovery ...... t and experimental validation.
@ast
Pharmacophore-based discovery ...... t and experimental validation.
@en
Pharmacophore-based discovery ...... t and experimental validation.
@nl
type
label
Pharmacophore-based discovery ...... t and experimental validation.
@ast
Pharmacophore-based discovery ...... t and experimental validation.
@en
Pharmacophore-based discovery ...... t and experimental validation.
@nl
prefLabel
Pharmacophore-based discovery ...... t and experimental validation.
@ast
Pharmacophore-based discovery ...... t and experimental validation.
@en
Pharmacophore-based discovery ...... t and experimental validation.
@nl
P2093
P2860
P50
P1476
Pharmacophore-based discovery ...... t and experimental validation.
@en
P2093
Judit Mihaly-Bison
Markus Binder
Patrick Markt
Stefan M Noha
Valery N Bochkov
P2860
P304
P356
10.1016/J.BMC.2011.09.056
P407
P577
2011-10-04T00:00:00Z